{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:34:51Z","timestamp":1777901691535,"version":"3.51.4"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jada.ada.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.adaj.2017.08.046","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T05:03:41Z","timestamp":1516770221000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeted cancer therapies"],"prefix":"10.1016","volume":"149","author":[{"given":"Eleni","family":"Georgakopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Stebbing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crispian","family":"Scully","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.adaj.2017.08.046_bib1","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-10-1040","article-title":"AACR Centennial series: the biology of cancer metastasis: historical perspective","volume":"70","author":"Talmadge","year":"2010","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.adaj.2017.08.046_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(05)70182-0","article-title":"Management of chemotherapy-induced side-effects","volume":"6","author":"Raji","year":"2005","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib3","doi-asserted-by":"crossref","first-page":"II","DOI":"10.1634\/theoncologist.1-3-120i","article-title":"Cancer drug development: new targets for cancer treatment","volume":"1","author":"Curt","year":"1996","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","article-title":"Discovery of small molecule cancer drugs: successes, challenges and opportunities","volume":"6","author":"Hoelder","year":"2012","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib7","doi-asserted-by":"crossref","first-page":"e009586","DOI":"10.1136\/bmjopen-2015-009586","article-title":"Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment","volume":"6","author":"Hill","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.adaj.2017.08.046_bib8","first-page":"213","article-title":"Magic bullets: paving the way in oral cancer therapy","volume":"2","author":"Rao","year":"2015","journal-title":"J\u00a0Adv Clin Res Ins"},{"key":"10.1016\/j.adaj.2017.08.046_bib9","unstructured":"Abramson RG. Overview of targeted therapies for\u00a0cancer. My Cancer Genome Web site. Available at: https:\/\/www.mycancergenome.org\/content\/molecular-medicine\/overview-of-targeted-therapies-for-cancer\/. Accessed November 5,\u00a02017."},{"issue":"11","key":"10.1016\/j.adaj.2017.08.046_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Eng J Med"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab: mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N\u00a0Eng J Med"},{"issue":"26","key":"10.1016\/j.adaj.2017.08.046_bib12","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for\u00a0HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Eng J Med"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Eng J Med"},{"issue":"19","key":"10.1016\/j.adaj.2017.08.046_bib14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Eng J Med"},{"issue":"5","key":"10.1016\/j.adaj.2017.08.046_bib15","first-page":"263","article-title":"Roles of EGFR and KRAS mutations in the treatment of patients with non\u2013small-cell lung cancer","volume":"36","author":"Langer","year":"2011","journal-title":"P\u00a0T"},{"issue":"6","key":"10.1016\/j.adaj.2017.08.046_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.adaj.2017.08.046_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-2423(10)51004-7","article-title":"EGFR and KRAS in colorectal cancer","volume":"51","author":"Markman","year":"2010","journal-title":"Adv Clin Chem"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1634\/theoncologist.2009-0167","article-title":"The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development","volume":"15","author":"Eng","year":"2010","journal-title":"Oncologist"},{"issue":"37","key":"10.1016\/j.adaj.2017.08.046_bib20","first-page":"5171","article-title":"KRAS mutation testing in metastatic colorectal cancer","volume":"18","author":"Tan","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"35","key":"10.1016\/j.adaj.2017.08.046_bib21","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.adaj.2017.08.046_bib22","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clinical Cancer Res"},{"issue":"11","key":"10.1016\/j.adaj.2017.08.046_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.2012-0311","article-title":"Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology","volume":"17","author":"Ou","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.adaj.2017.08.046_bib24","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1590\/1414-431X20144099","article-title":"Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data","volume":"47","author":"Jorge","year":"2014","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2016.0031","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 4","volume":"14","author":"Ettinger","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.adaj.2017.08.046_bib26","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1245\/s10434-008-0177-7","article-title":"A\u00a0randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis","volume":"16","author":"McAuliffe","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"26","key":"10.1016\/j.adaj.2017.08.046_bib27","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Eng J Med"},{"issue":"23","key":"10.1016\/j.adaj.2017.08.046_bib28","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-08-2742","article-title":"Targeting the RET pathway in thyroid cancer","volume":"15","author":"Wells","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.adaj.2017.08.046_bib29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.adaj.2017.08.046_bib30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.adaj.2017.08.046_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-3284-1-6","article-title":"Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma","volume":"1","author":"Matta","year":"2009","journal-title":"Head Neck Oncol"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N\u00a0Eng J Med"},{"issue":"suppl May 2016","key":"10.1016\/j.adaj.2017.08.046_bib33","first-page":"e89829","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012","volume":"34","author":"Mehra","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.adaj.2017.08.046_bib35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1652","article-title":"HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors","volume":"9","author":"Spector","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"18","key":"10.1016\/j.adaj.2017.08.046_bib37","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/jco.2006.24.18_suppl.5511","article-title":"Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): response by tumor EGFR and HER2\/neu status [Abstract]","volume":"24","author":"Gillison","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.adaj.2017.08.046_bib38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"issue":"15","key":"10.1016\/j.adaj.2017.08.046_bib39","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/cncr.30067","article-title":"Capecitabine and lapatinib for the first-line treatment of metastatic\/recurrent head and neck squamous cell carcinoma","volume":"122","author":"Weiss","year":"2016","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.adaj.2017.08.046_bib40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.bdj.2015.439","article-title":"Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare","volume":"218","author":"Georgakopoulou","year":"2015","journal-title":"Br Dent J"},{"issue":"4","key":"10.1016\/j.adaj.2017.08.046_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/jicd.12102","article-title":"Orofacial adverse effects of biological agents","volume":"6","author":"Georgakopoulou","year":"2015","journal-title":"J\u00a0Investig Clin Dent"},{"issue":"6","key":"10.1016\/j.adaj.2017.08.046_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1601-0825.2012.01919.x","article-title":"Biologics in oral medicine: principles of use and practical considerations","volume":"18","author":"O'Neill","year":"2012","journal-title":"Oral Dis"},{"issue":"7","key":"10.1016\/j.adaj.2017.08.046_bib43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1601-0825.2012.01918.x","article-title":"Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosis","volume":"18","author":"O'Neill","year":"2012","journal-title":"Oral Dis"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1601-0825.2012.01931.x","article-title":"Biologics in oral medicine: ulcerative disorders","volume":"19","author":"O'Neill","year":"2013","journal-title":"Oral Dis"},{"issue":"10","key":"10.1016\/j.adaj.2017.08.046_bib45","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral and Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","article-title":"Bisphosphonates in cancer therapy","volume":"257","author":"Stresing","year":"2007","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.adaj.2017.08.046_bib47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Eng J Med"},{"issue":"16","key":"10.1016\/j.adaj.2017.08.046_bib48","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Eng J Med"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.adaj.2017.08.046_bib51","doi-asserted-by":"crossref","unstructured":"Hernandez M, Phulpin B, Mansuy L, Droz D. Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review [published online ahead of print October 25, 2016]. J Oral Pathol Med. https:\/\/doi.org\/10.1111\/jop.12516.","DOI":"10.1111\/jop.12516"},{"issue":"12","key":"10.1016\/j.adaj.2017.08.046_bib52","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Brit J Canc"},{"issue":"4","key":"10.1016\/j.adaj.2017.08.046_bib53","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/SAP.0b013e31824e5e57","article-title":"Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon","volume":"71","author":"Sharma","year":"2013","journal-title":"Ann Plast Surg"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib54","first-page":"311","article-title":"Targeted therapies: a new generation of\u00a0cancer treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am Fam Physician"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0007-117X(82)90015-4","article-title":"Oral manifestation in cyclic neutropenia","volume":"20","author":"Scully","year":"1982","journal-title":"Brit J Oral Surg"},{"issue":"15","key":"10.1016\/j.adaj.2017.08.046_bib56","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for\u00a0the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients\u00a0with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.adaj.2017.08.046_bib57","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.adaj.2017.08.046_bib58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.adaj.2017.08.046_bib59","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A\u00a0phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.adaj.2017.08.046_bib60","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.adaj.2017.08.046_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2010-0263","article-title":"Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities","volume":"16","author":"Kollmannsberger","year":"2011","journal-title":"Oncologist"},{"issue":"suppl 2","key":"10.1016\/j.adaj.2017.08.046_bib62","first-page":"S41","article-title":"Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects","volume":"1","author":"Kollmannsberger","year":"2007","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.adaj.2017.08.046_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-016-0153-9","article-title":"A\u00a0guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the World Workshop on Oral Medicine VI","volume":"17","author":"Wolff","year":"2017","journal-title":"Drugs R D"},{"issue":"12","key":"10.1016\/j.adaj.2017.08.046_bib64","doi-asserted-by":"crossref","first-page":"e49717","DOI":"10.1371\/journal.pone.0049717","article-title":"Efficacy and\u00a0safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials","volume":"7","author":"Fang","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.adaj.2017.08.046_bib65","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/CAD.0b013e3283462086","article-title":"Oral mucositis","volume":"22","author":"Sonis","year":"2011","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.adaj.2017.08.046_bib66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.oraloncology.2011.03.028","article-title":"Oral complications of targeted cancer therapies: a narrative literature review","volume":"47","author":"Watters","year":"2011","journal-title":"Oral Oncol"},{"issue":"10","key":"10.1016\/j.adaj.2017.08.046_bib67","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.adaj.2017.08.046_bib69","article-title":"Oral mucositis and stomatitis associated with conventional and targeted anticancer therapy","author":"Parkhill","year":"2013","journal-title":"J\u00a0Pharmacovigilance"},{"issue":"8","key":"10.1016\/j.adaj.2017.08.046_bib70","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.adaj.2017.08.046_bib71","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/cncr.24265","article-title":"Neoadjuvant chemotherapy\/gefitinib followed by concurrent chemotherapy\/radiation therapy\/gefitinib for patients with locally advanced squamous carcinoma of the head and neck","volume":"115","author":"Hainsworth","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":"Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial","volume":"13","author":"Untch","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.adaj.2017.08.046_bib73","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","article-title":"Nilotinib in patients with metastatic melanoma harboring KIT gene aberration","volume":"30","author":"Cho","year":"2012","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib75","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejon.2011.05.001","article-title":"Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group","volume":"16","author":"Edmonds","year":"2012","journal-title":"Eur J Oncol Nurs"},{"issue":"15","key":"10.1016\/j.adaj.2017.08.046_bib76","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2174\/1381612822666160219120842","volume":"22","author":"Miyano","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.adaj.2017.08.046_bib77","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fonc.2014.00238","article-title":"Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR\u2013TKIs","volume":"4","author":"Melosky","year":"2014","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.adaj.2017.08.046_bib78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/154405910708600604","article-title":"Orofacial pain in cancer, part I: mechanisms","volume":"86","author":"Benoliel","year":"2007","journal-title":"J\u00a0Dent Res"},{"issue":"6","key":"10.1016\/j.adaj.2017.08.046_bib79","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/154405910708600605","article-title":"Orofacial pain in cancer, part II: clinical perspectives and management","volume":"86","author":"Epstein","year":"2007","journal-title":"J\u00a0Dent Res"},{"issue":"6","key":"10.1016\/j.adaj.2017.08.046_bib80","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/COC.0b013e318172d5de","article-title":"High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers","volume":"31","author":"Sharp","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","article-title":"Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review","volume":"17","author":"Boers-Doets","year":"2012","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.adaj.2017.08.046_bib82","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1365-4632.2006.03171.x","article-title":"Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases","volume":"45","author":"Pascual","year":"2006","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000063899","article-title":"Oral lichenoid reaction to imatinib (STI 571, Gleevec)","volume":"205","author":"Lim","year":"2002","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib84","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1345\/aph.1K592","article-title":"Sunitinib adverse event: oral bullous and lichenoid mucositis","volume":"43","author":"Mignogna","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"16","key":"10.1016\/j.adaj.2017.08.046_bib85","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib86","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/000163501750266774","article-title":"Immune mechanisms in oral lichen planus","volume":"59","author":"Thornhill","year":"2001","journal-title":"Acta Odontol Scand"},{"issue":"4","key":"10.1016\/j.adaj.2017.08.046_bib87","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1002\/phar.1383","article-title":"Bortezomib-induced Sweet's syndrome confirmed by rechallenge","volume":"34","author":"Zobniw","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.adaj.2017.08.046_bib88","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/1346-8138.12430","article-title":"Case of vemurafenib-induced Sweet's syndrome","volume":"41","author":"Yorio","year":"2014","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib89","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2015.01.018","article-title":"Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer","volume":"88","author":"Koizumi","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib90","first-page":"107","article-title":"Taste bud regeneration and the search for taste progenitor cells","volume":"148","author":"Miura","year":"2010","journal-title":"Arch Ital Biol"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib91","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib92","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.tripleo.2011.03.046","article-title":"Are we ready to blame imatinib for palatal pigmentation?","volume":"112","author":"Torres-Pereira","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"5","key":"10.1016\/j.adaj.2017.08.046_bib93","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.tripleo.2010.11.006","article-title":"Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases","volume":"111","author":"Mattsson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"8","key":"10.1016\/j.adaj.2017.08.046_bib94","first-page":"24","article-title":"Diffuse pigmentation of the palate","volume":"100","author":"Lewis","year":"2009","journal-title":"J\u00a0Okla Dent Assoc"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12105-011-0325-4","article-title":"Mucosal pigmentation caused by imatinib: report of three cases","volume":"6","author":"Li","year":"2012","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.adaj.2017.08.046_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209335","article-title":"Mucosal pigmentation of the hard palate in a patient taking imatinib","author":"Lyne","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.adaj.2017.08.046_bib97","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/817094","article-title":"A\u00a0rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia","author":"Romeo","year":"2015","journal-title":"Case Rep Dent"},{"issue":"5","key":"10.1016\/j.adaj.2017.08.046_bib98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D3498194BX","article-title":"Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature","volume":"17","author":"Wong","year":"2011","journal-title":"Dermatol Online J"},{"issue":"4","key":"10.1016\/j.adaj.2017.08.046_bib99","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00520-008-0536-8","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.adaj.2017.08.046_bib100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MPH.0b013e318033a76c","article-title":"Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia","volume":"29","author":"Singh","year":"2007","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.adaj.2017.08.046_bib101","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.adaj.2017.08.046_bib102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D3472203P2","article-title":"Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST","volume":"14","author":"Alexandrescu","year":"2008","journal-title":"Dermatol Online J"},{"issue":"5-6","key":"10.1016\/j.adaj.2017.08.046_bib103","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.currproblcancer.2016.06.001","article-title":"Toxicities associated with head and neck cancer treatment and oncology-related clinical trials","volume":"40","author":"Villa","year":"2016","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"10.1016\/j.adaj.2017.08.046_bib104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cyto.2012.03.027","article-title":"Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy","volume":"59","author":"Wang","year":"2012","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.adaj.2017.08.046_bib105","first-page":"712","article-title":"Toll-like receptor 4 signaling contributes to paclitaxel-induced peripheral neuropathy","volume":"15","author":"Li","year":"2014","journal-title":"J\u00a0Pain"},{"issue":"9","key":"10.1016\/j.adaj.2017.08.046_bib106","first-page":"1588","article-title":"Cytotoxic chemotherapy-induced odontalgia: a differential diagnosis for dental pain","volume":"36","author":"Zadik","year":"2010","journal-title":"J\u00a0Endod"},{"issue":"9","key":"10.1016\/j.adaj.2017.08.046_bib107","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand\u2013foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.adaj.2017.08.046_bib108","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1634\/theoncologist.12-4-443","article-title":"Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer","volume":"12","author":"Los","year":"2007","journal-title":"Oncologist"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817717308036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817717308036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T17:37:15Z","timestamp":1693503435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817717308036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0002817717308036"],"URL":"https:\/\/doi.org\/10.1016\/j.adaj.2017.08.046","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted cancer therapies","name":"articletitle","label":"Article Title"},{"value":"The Journal of the American Dental Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adaj.2017.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Dental Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}